HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $19.00 target price on the biotechnology company’s stock.
Separately, StockNews.com started coverage on shares of BioLineRx in a research report on Thursday, August 17th. They issued a sell rating for the company.
BioLineRx Price Performance
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.14). During the same period in the previous year, the business earned ($0.16) earnings per share. As a group, sell-side analysts predict that BioLineRx will post -0.65 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its holdings in BioLineRx by 278.0% during the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 189,678 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new stake in shares of BioLineRx during the 1st quarter worth about $178,000. Envestnet Asset Management Inc. bought a new stake in shares of BioLineRx during the 1st quarter worth about $88,000. Finally, LPL Financial LLC grew its stake in BioLineRx by 152.7% in the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 71,134 shares during the last quarter. 2.01% of the stock is owned by institutional investors and hedge funds.
BioLineRx Company Profile
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- Five stocks we like better than BioLineRx
- 3 Small Caps With Big Return Potential
- 3 Takeaways from the August Inflation Report
- What is a SEC Filing?
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- How to Invest and Trade Chinese Stocks
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.